Wealth Enhancement Advisory Services LLC Buys 1,766 Shares of Haleon plc (NYSE:HLN)

Wealth Enhancement Advisory Services LLC grew its stake in shares of Haleon plc (NYSE:HLN) by 3.0% during the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 61,016 shares of the company’s stock after purchasing an additional 1,766 shares during the quarter. Wealth Enhancement Advisory Services LLC’s holdings in Haleon were worth $646,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Lake Street Advisors Group LLC increased its position in Haleon by 5.4% during the third quarter. Lake Street Advisors Group LLC now owns 22,395 shares of the company’s stock worth $237,000 after buying an additional 1,143 shares during the last quarter. Ballentine Partners LLC raised its stake in Haleon by 53.1% in the 3rd quarter. Ballentine Partners LLC now owns 22,831 shares of the company’s stock valued at $242,000 after acquiring an additional 7,918 shares during the period. International Assets Investment Management LLC bought a new stake in Haleon in the 3rd quarter valued at $3,700,000. GAM Holding AG lifted its holdings in Haleon by 0.8% during the 3rd quarter. GAM Holding AG now owns 849,284 shares of the company’s stock valued at $8,985,000 after purchasing an additional 6,891 shares during the last quarter. Finally, Signaturefd LLC boosted its position in Haleon by 5.7% during the third quarter. Signaturefd LLC now owns 123,067 shares of the company’s stock worth $1,302,000 after purchasing an additional 6,612 shares during the period. Institutional investors own 6.67% of the company’s stock.

Haleon Stock Performance

Shares of NYSE:HLN opened at $9.60 on Friday. Haleon plc has a 12-month low of $7.89 and a 12-month high of $10.80. The company’s 50 day moving average price is $10.21 and its two-hundred day moving average price is $9.29. The firm has a market cap of $43.43 billion, a PE ratio of 28.22, a PEG ratio of 2.93 and a beta of 0.30. The company has a quick ratio of 0.58, a current ratio of 0.84 and a debt-to-equity ratio of 0.44.

Wall Street Analysts Forecast Growth

HLN has been the topic of several research analyst reports. The Goldman Sachs Group lowered shares of Haleon from a “buy” rating to a “neutral” rating in a research report on Tuesday, August 6th. Morgan Stanley boosted their price objective on Haleon from $9.90 to $10.95 and gave the stock an “overweight” rating in a report on Friday, September 20th. Berenberg Bank assumed coverage on Haleon in a research note on Tuesday, August 6th. They set a “buy” rating on the stock. Finally, UBS Group upgraded Haleon to a “strong-buy” rating in a research note on Tuesday, October 1st. One equities research analyst has rated the stock with a hold rating, four have issued a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, Haleon currently has an average rating of “Buy” and a consensus price target of $10.95.

Haleon Company Profile

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands.